Viswanadhapalli, Suryavathi
Ma, Shihong
Sareddy, Gangadhara Reddy
Lee, Tae-Kyung
Li, Mengxing
Gilbreath, Collin
Liu, Xihui
Luo, Yiliao
Pratap, Uday P.
Zhou, Mei
Blatt, Eliot B.
Kassees, Kara
Arteaga, Carlos
Alluri, Prasanna
Rao, Manjeet
Weintraub, Susan T.
Tekmal, Rajeshwar Rao
Ahn, Jung-Mo
Raj, Ganesh V.
Vadlamudi, Ratna K. http://orcid.org/0000-0003-2849-4076
Funding for this research was provided by:
National Cancer Institute (NIH CA223828-01, P30CA054174-17)
Max and Minnie Tomerlin Voelcker Fund (Young Investigator Grant)
Welch Foundation (AT-1595)
Article History
Received: 10 June 2019
Accepted: 13 November 2019
First Online: 26 December 2019
Ethics approval and consent to participate
: All animal experiments were performed after obtaining UTHSA IACUC approval using the methods in the approved protocol. For explant experiments, de-identified patient tumors were obtained from the UTSW Tissue Repository after institutional review board approval (STU-032011-187) [CitationRef removed].
: Not applicable
: J-MA, GVR, and RV are joint holders on issued and pending patents on ERX-11. CA serves or has served in an advisory role to Novartis, Merck, Lilly, Radius, Sanofi, Daiichi Sankyo, H3 Biomedicine, Puma, TAIHO Oncology, Symphogen, Bayer, Athenex, G1 Therapeutics, Petra Pharma and Celgene. He also has stock options in Provista and Y-TRAP. He has or has had grant support from Lilly, Pfizer, Bayer, Takeda and Radius. He also serves in the Scientific Advisory Board of the Komen Foundation. The other authors declare that they have no competing interests.